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Background: Chronic Stenotrophomonas maltophilia infection is an independent risk factor for severe pulmonary exacerbations in cystic ﬁbrosis
(CF) patients. The goal of this study was to determine the effect of chronic S. maltophilia infection on mortality and the need for lung
transplantation in a longitudinal study of children and adults with CF.
Methods: This was a cohort study of CF patients from the Hospital for Sick Children and St Michael's Hospital (Toronto, Canada) from 1997 to
2008. A Cox Regression model was used to estimate the hazard ratio (HR) to time of death or lung transplantation adjusting for age, gender,
genotype, pancreatic status, CF related diabetes (CFRD), forced expiratory volume in 1 s (FEV1), body mass index, number of pulmonary
exacerbations, Pseudomonas aeruginosa, Burkholderia cepacia complex, Aspergillus and chronic S. maltophilia infection.
Results: A total of 687 patients were followed over the 12 year study period; 95 patients underwent a lung transplantation (of which 26 died) and
an additional 49 patients died (total 144 events). In a Cox Regression model adjusting for baseline FEV1, baseline infection with B. cepacia
complex (HR 1.72, 95% CI 1.09–2.71) and baseline chronic S. maltophilia infection (HR 2.80, 95% CI 1.65–4.76) were signiﬁcantly associated
with death or lung transplant. However, in a time-varying model, infection with B. cepacia complex and chronic S. maltophilia infection were no
longer signiﬁcant.
Conclusions: Baseline chronic S. maltophilia infection is associated with an almost three-fold increased risk of death or lung transplant in CF
patients. It is still unclear, however, whether chronic S. maltophilia infection is simply a marker of severity of disease and ultimate mortality or
whether it is causally related to disease progression.
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We have recently shown that chronic pulmonary infection with
Stenotrophomonas maltophilia is an independent risk factor for CF
pulmonary exacerbations requiring hospitalization and antibiotics
[1]. As increasing number of acute pulmonary exacerbations is
associated with increased mortality in cystic fibrosis (CF) [2], CFby Elsevier B.V. All rights reserved.
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risk of death than CF patients without S. maltophilia infection.
Previous studies have shown that, in addition to a lack of effect on
lung function decline [3], detection of S. maltophilia in the
respiratory tract of individuals with CF was not associated with
increased mortality [4]. However, this study did not distinguish
between intermittent and chronic infection; subsequent studies of
methicillin-resistant Staphylococcus aureus (MRSA) infection in
CF, for example, have shown that persistence of infection is an
important determinant of poor clinical outcomes [5,6]. The aim of
this studywas thus to determine the effect of chronic S. maltophilia
infection on mortality and the need for lung transplantation in a
pediatric and adult CF cohort.
2. Materials and methods
2.1. Study design and patient population
This was a longitudinal cohort study of patients with CF
followed at the Hospital for Sick Children and St Michael's
Hospital (Toronto, Canada) from 1997 to 2008. The data for
this study was extracted from the Toronto Cystic Fibrosis
Database housed at the Hospital for Sick Children. This encounter
based database prospectively collects information from pediatric
and adult CF subjects from every visit including sputum
microbiology, medications and pulmonary function testing [7].
Patients were excluded if they could not produce sputum or if they
were unable to perform reproducible spirometry.
During this study period, there were no standard treatment
protocols for S. maltophilia given the unknown significance of
infection with this organism in CF. Burkholderia cepacia
complex infections were treated with antimicrobials at the time
of pulmonary exacerbations. CF patients with P. aeruginosa
infections were treated with antibiotics at the time of a
pulmonary exacerbation. In addition, CF patients with early
P. aeruginosa infection were treated with inhaled tobramycin
for eradication and CF patients with chronic P. aeruginosa
infection were treated with inhaled tobramycin for chronic
maintenance therapy [8].
This study was approved by the Research Ethics Board at
the Hospital for Sick Children and St Michael's Hospital.
2.2. Statistical analysis
Baseline characteristics for the cohort were defined based on
data from the first year of observation. Categorical variables
were expressed as proportions where as continuous variables
were expressed as means with standard deviations (SD) or
median and Inter quartile Range (IQR). Two Cox Regression
models were used to estimate the hazard ratio from time of
entry into cohort to time of death from any cause or lung
transplantation. In the first model, the following variables were
included and defined at baseline [2]: age (years), year of entry
into cohort, gender (male/female), genotype (homozygous
ΔF508, other), pancreatic insufficiency (defined by enzyme
usage), CF related diabetes (CFRD) (presence or absence based
on oral glucose tolerance test), forced expiratory volume in 1 s(FEV1 in percent predicted), body mass index (BMI), annual
number of pulmonary exacerbations requiring hospitalizations and
antibiotics, any P. aeruginosa B. cepacia complex or Aspergillus
infection and chronic S. maltophilia infection (≥2 positive
sputum or bronchoalveolar cultures for S. maltophilia in previous
12 months) [1]. Intermittent S. maltophilia infection was defined
as previously (one positive sputum or bronchoalveolar culture for
S. maltophilia in a given year or a previous positive culture) [1].
As Aspergillus culture results were recorded in the Toronto CF
Database beginning only in 1999, baseline study data for
Aspergillus infection was obtained from 1999.
In the second model, the same variables were included but the
following variables were analyzed as time-varying: FEV1 in
percent predicted, BMI, annual number of pulmonary exacerba-
tions, presence of P. aeruginosa infection, B. cepacia complex
infection and chronic S. maltophilia infection. Medicaid insurance
was not investigated since Canada has universal healthcare
insurance. MRSA and non-tuberculous mycobacteria were not
included due to their low prevalence in the CF population in
Canada and in our center [9,10]. Statistical analysis was performed
using SAS (version 9.2; SAS Institute Inc., Cary, NC). All p
values were 2-sided. A p-value of 0.05 or less was considered
statistically significant.
3. Results
3.1. Baseline patient characteristics and survival without
lung transplant
A total of 687 CF patients were followed over the 12 year
study period. Table 1 represents the baseline characteristics of
patients with chronic, intermittent and never having had
S. maltophilia infection as previously defined [1]. The three
patient groups had similar lengths of follow-up during the
study. CF patients with chronic S. maltophilia infection at study
entry were younger, had lower FEV1 % predicted, were less
likely to have B. cepacia complex infection but more likely to
have Aspergillus infection compared to patients who had never
had S. maltophilia infection.
Over the study period, 95 patients underwent a lung
transplantation (of which 26 died) and an additional 49 patients
died (total 144 events). Fig. 1 depicts the Kaplan–Meier curve of
overall survival without lung transplantation over time of study
patients according to their baseline S. maltophilia infection status.
Patients with chronic S. maltophilia infection had significantly
lower survival without lung transplantation, with 21 events
(4 deaths, 17 transplants) over the study period, compared to
patients with intermittent (3 events: no deaths, 3 transplants) or no
(120 events: 45 deaths, 75 transplants) S. maltophilia infection
(log-rank p valueb0.0001). Of note, of the 44 patients with
chronic S. maltophilia at baseline, 29 (66%) still had chronic
S. maltophilia at the time of death/transplant or at the end of
study; of the 77 patients with B. cepacia complex at baseline, 59
(77%) were still B. cepacia positive at the time of death/transplant
or at the end of study; and of the 305 patients with P. aeruginosa
at baseline, 165 (54%) were still P. aeruginosa positive at the
time of death/transplant or at the end of study.
Table 1
Baseline cohort characteristics.
Chronic Intermittent Never
S. maltophilia (n=44) S. maltophilia (n=21) S. maltophilia (n=622)
Follow-up time (years), median (IQR) 10.7 (7.5–12.0) 12.0 (10.3–12.0) 12.0 (10.5–12.0)
Age (years), median (IQR) 15.4 (8.4–26.3) 11.3 (4.6–19.8) 17.4 (7.6–27.6)
Male, n (%) 22 (50) 12 (57.1) 350 (56.3)
Homozygous ΔF508, n (%) 19 (43.2) 9 (42.8) 253 (40.7)
Pancreatic insufficient, n (%) 39 (88.6) 18 (85.7) 500 (80.4)
CF related diabetes mellitus, n (%) 3 (6.8) 2 (9.5) 63 (10.1)
Body mass index, median (IQR) 19.4 (15.9–21.4) 19.6 (15.7–20.4) 20.1 (16.9–22.8)
FEV1 % predicted, mean (SD) 50.3 (24.9) 45.2 (18.1) 69.2 (25.2)
P. aeruginosa infection, n (%) 19 (43.2) 9 (42.9) 276 (44.4)
B. cepacia complex infection, n (%) 0 (0) 1 (4.8) 75 (12.1)
Aspergillus infection a, n (%) 11 (25) 2 (9.5) 45 (7.2)
IQR: interquartile range.
FEV1: forced expiratory volume in 1 s.
SD: standard deviation.
a Based on 1999 data.
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In order to account for other factors that may influence
clinical outcomes, Cox Regression modeling was used to
determine the effect of chronic S. maltophilia infection on
mortality and the need for lung transplantation. In the first Cox
model, the following variables were analyzed by defining them
at baseline: age, year of entry into cohort, gender, genotype,
pancreatic insufficiency, CFRD, FEV1 percent predicted,
BMI, annual number of pulmonary exacerbations, presence
of P. aeruginosa infection, B. cepacia complex infection and
chronic S. maltophilia infection. Non-significant variables
were then removed from the model in step-wise fashion. The
resulting significant hazard ratios for time to death or lung
transplantation are represented in Table 2A. Even after
adjusting for baseline FEV1, baseline infection with either
B. cepacia complex (HR 1.72, 95% CI 1.09–2.71) or chronic
S. maltophilia infection (HR 2.80, 95% CI 1.65–4.76) was
significantly associated with death or lung transplant. Addi-
tional significant hazard ratios included other markers of
severity of disease such as homozygous ΔF508 genotype
(HR 1.57, 95% CI 1.07–2.31) and lower FEV1 % predicted
(HR 1.07, 95% CI 1.06–1.08). Of note, neither infection with
intermittent S. maltophilia nor P. aeruginosa was associated
with death or transplant.
A second Cox Regression model was then used to analyze the
effects of lung function, nutritional status, pulmonary exacerba-
tions and infection with P. aeruginosa, B. cepacia complex and
chronic S. maltophilia on death or transplant in a time-varying
manner (Table 2B). In this model, infection with B. cepacia
complex and chronic S. maltophilia infection were no longer
significant. Only lower FEV1, homozygous ΔF508 genotype,
greater annual number of pulmonary exacerbations and CFRD had
significant hazard ratios for time to death or lung transplant in the
reduced model. When the risk of death or transplant was assessed
in the Cox model using only time-varying infection status,
B. cepacia complex (pb0.0001) but not chronic S. maltophilia
(p=0.70) or P. aeruginosa (p=0.08), were significant risk factors.4. Discussion
This study is the first to demonstrate that, even after
adjusting for FEV1, baseline chronic S. maltophilia infection
was associated with an almost three-fold increased risk of death
or lung transplant in CF patients, even higher than that seen
with B. cepacia complex infection. In a time-varying model that
includes lung function, however, the effects of chronic
S. maltophilia and B. cepacia complex infection on mortality
and the need for lung transplantation were no longer significant.
Only one other study has used survival analysis to specifically
examine the effect of S. maltophilia on mortality in patients with
CF. The parallel cohort study by Goss et al. using the Cystic
Fibrosis Foundation Registry assessed almost twenty thousand
individuals with CF over a 6 year study period [4]. Although the
study by Goss et al. had significantly more patients than this
current study, it had a much shorter follow up period and did not
distinguish between intermittent and chronic colonization.
Interestingly, the effects of baseline chronic S. maltophilia
infection on mortality and lung transplantation in our study were
only seen with chronic infection and not with intermittent
infection. In a multivariate model using S. maltophilia infection
as a time-dependent variable, Goss et al. found that S. maltophilia
infection was not an independent risk factor for death, which is
consistent with the results from this current dataset. However, the
authors did not use baseline infection status in their model; in our
study, baseline chronic S. maltophilia infection had significant
hazard ratios for death or transplant, even after adjusting for lung
function.
There are two possible explanations for why chronic
S. maltophilia and B. cepacia complex infection were signifi-
cantly associated with death or transplant in the baseline model
but not in the time-varying model. The first is that the infection
status at baseline may not necessarily be the same as the infection
status in the year before death (time-varying model). Only
two-thirds of the patients with chronic S. maltophilia at baseline
were classified as chronic in the year before death or transplant
due to the changing pattern of infection over time. Although
Fig. 1. Kaplan–Meier curve of overall survival without lung transplantation
over time of patients with baseline chronic S. maltophilia infection (dashed line)
compared to patients with intermittent (dotted line) or never having had (solid
line), S. maltophilia infection (log-rank p valueb0.0001).
Table 2B
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baseline had that same infection in the year before death/
transplant, it is clear that transient infection with B. cepacia
complex infection does occur in CF patients. This may be due to
the changing epidemiology of B. cepacia complex infection in
CF. With stricter infection control measures, the proportion of
B. cepacia complex infections that are due to B. cenocepacia are
decreasing in the Canadian CF population, especially within the
Toronto clinics, and non-cenocepacia infections, such as due to
B. multivorans, are more likely to be transient (unpublished data,
Dr James Zlosnik). The changing epidemiology may also explain
why in earlier studies using the Canadian Patient Data Registry,
B. cepacia complex infection was a significant risk factor for
death when examined as a time-varying variable [11]. Many of
these patients died of cepacia syndrome and one would thus
expect B. cenocepacia to be cultured in the year before death
[12]. These individuals, however, are no longer represented in
this current dataset and non-cenocepacia Burkholderiamay have
less of a direct, negative clinical impact than cenocepacia in CF
patients, as suggested by other studies [13–15].
The other explanation for why chronic S. maltophilia and
B. cepacia infection are significant in a baseline but not a
time-varying model is that these organisms, which are intrinsi-
cally multi-drug resistant and thus difficult to eradicate with
antibiotic treatment, may contribute to mortality by causing
declining lung function. By adjusting for FEV1 every year in aTable 2A
Significant hazard ratios for time to death or lung transplantation using baseline
model.
Variable Hazard ratio 95% CI p value
Lower FEV1 % predicted 1.07 1.06–1.08 b0.0001
Homozygous ΔF508 1.57 1.07–2.31 0.02
B. cepacia complex infection 1.72 1.09–2.71 0.02
Chronic S. maltophilia infection 2.80 1.65–4.76 0.0001time-varying model, the effect of these infections may no longer
be significant. Using only infection status as variables in the
Cox model, B. cepacia infection, but not chronic S. maltophilia
infection, was significantly associated with death or lung
transplant, suggesting that the effect of B. cepacia complex
infection on mortality in CF may be reflected by lung function
decline.
There are advantages and disadvantages to modeling infection
status at baseline or as time-varying in survival analyses. The
advantage of modeling infection status at baseline is that one can
identify a group of patients that may have suffered an initial
injury due to the infection that may result in subsequent declining
lung function and death. The disadvantage is that, although lung
function can be adjusted for in models using baseline infection
status, determining infection at baseline cannot account for the
direct effects of this infection over time on ultimate mortality.
Alternatively, a model that determines infection over time
(time-varying analyses) will only consider the infection status in
the year before death and may not capture effects that have
occurred over a lifetime. In addition, if a model is adjusting for
variables, such as FEV1, that are on the causal pathway of
infection leading to death, the model may only detect the effect of
FEV1 on mortality.
Our study did not identify P. aeruginosa infection as a
significant predictor of death or lung transplant in both the
baseline and time-varying model that included lung function.
This has been described in other studies [2,6,11,16–18]. A
possible explanation for this finding is the widespread effective
use of inhaled antibiotics. This chronic suppressive antibiotic
treatment of P. aeruginosa pulmonary infection may be
mitigating the effects of this organism on mortality [19]. In
addition, antibiotic therapy may be changing the pattern of
P. aeruginosa infection in CF; in our study, only half of the
patients with P. aeruginosa at the start of the study were culture
positive for P. aeruginosa at the end of the study or at the time
of death/transplant. Studies accounting for P. aeruginosa
antibiotic therapy have been able to demonstrate an effect of
this organism on CF mortality [4]. In contrast, B. cepacia
complex and S. maltophilia are intrinsically multi-drug resistant
and there is no suppressive antimicrobial therapy proven to be
effective for CF patients with these pulmonary infections,
leading to greater hazard ratios for death [20,21].
This study has several limitations. The primary weakness is
the relatively small number of patients from one center (the
Toronto CF center) included in this analysis. This limits the
number of events and the power to detect significant covariatesSignificant hazard ratios for time to death or lung transplantation using time-varying
model.
Variable Hazard ratio 95% CI p value
Lower FEV1 % predicted 1.09 1.07–1.10 b0.0001
Homozygous ΔF508 1.53 1.07–2.19 0.02
Annual no. pulmonary exacerbations 1.21 1.02–1.42 0.03
CF related diabetes 2.42 1.57–3.73 b0.0001
FEV1: forced expiratory volume in 1 s.
CI: confidence intervals.
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events, we combined deaths and lung transplantation as the
primary outcome as others have done previously [22].
Although risk factors for death are used to guide the indications
for lung transplantation (in particular FEV1 predicted b30%)
[7], it is possible that there are other risk factors that are
different for the two outcomes and that chronic S. maltophilia
infection may be associated with one outcome and not the
other, which this study would not detect. Ultimately, this study
design cannot determine causality and only identifies associa-
tions. Finally, defining chronic infection can also be problem-
atic. Although the Leeds definition of chronic infection as
N50% of cultures positive is more established, we chose a
definition of 2 or more cultures positive in a year given our
previous finding that this population with S. maltophilia
infection was at increased risk of pulmonary exacerbation and
thus likely had more severe disease [1]. However, a chronic
infection definition of 2 or more positive cultures in 12 months
is limited by the fact that it does not take into account the
number of cultures a patient may have had in a given year.
In conclusion, this study demonstrated that, in a multivariate
model adjusting for lung function and other markers of severity
of disease, baseline chronic S. maltophilia infection was
associated with an almost three-fold increased risk of death or
lung transplant in CF patients. However, this effect was not
seen when chronic S. maltophilia infection was analyzed in a
time-dependent fashion in a model with lung function,
highlighting the difficulties in deciphering the direct effects of
bacterial pulmonary infection on mortality in CF. Prospective
interventional studies are needed to determine if antimicrobial
treatment of CF patients with chronic S. maltophilia infection
can alter the course of their disease and improve their clinical
outcomes.
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